文献速递创伤与烧伤儿科与产科急症重症综合管理与镇静镇痛

神经药理学代谢组学在儿童重型颅脑创伤中的探索性应用

Exploratory Application of Neuropharmacometabolomics in Severe Childhood Traumatic Brain Injury.
PubMed 文献 · Crit Care Med · 2018-01-01
一句话结论在儿童重型颅脑创伤中,丙磺舒联合N-乙酰半胱氨酸与安慰剂相比,脑脊液中7条谷胱甘肽相关通路和2个网络富集,支持该联合治疗的靶点 engagement。

本研究为一项随机安慰剂对照试验的脑脊液代谢组学分析,纳入12例2-18岁重型颅脑创伤患儿和5例年龄匹配对照,患儿经鼻/口胃管接受丙磺舒(25 mg/kg)和N-乙酰半胱氨酸(140 mg/kg)或安慰剂。首次给药24小时后采集脑脊液,进行代谢组学通路和网络分析。结果显示,与安慰剂组相比,丙磺舒联合N-乙酰半胱氨酸组脑脊液中有7条谷胱甘肽中心通路和2个网络富集,并鉴定出若干新的代谢通路。作者认为该概念验证性神经药理学代谢组学评估支持该联合治疗在儿童重型颅脑创伤中的治疗靶点 engagement。

要点

  • 在12例重型颅脑创伤患儿中,丙磺舒(25 mg/kg)联合N-乙酰半胱氨酸(140 mg/kg)经鼻/口胃管给药,与安慰剂相比,脑脊液代谢组学显示7条谷胱甘肽中心通路和2个网络富集。
  • 该研究为随机安慰剂对照试验的脑脊液代谢组学分析,纳入12例2-18岁重型颅脑创伤患儿和5例年龄匹配对照,首次给药24小时后采样。
  • 通路和网络分析还鉴定出若干以丙磺舒可抑制转运体底物为组分的额外通路/网络,提供机制验证。
  • 作者结论认为该概念验证性评估支持丙磺舒联合N-乙酰半胱氨酸在儿童重型颅脑创伤中的治疗靶点 engagement。

适用人群与场景

  • 2-18岁儿童,重型颅脑创伤后入住36张床位的大学附属儿童医院PICU。
  • 对照为年龄匹配的受试者。

处置流程与药物剂量

  • 丙磺舒25 mg/kg和N-乙酰半胱氨酸140 mg/kg,或安慰剂,经鼻/口胃管给药。
  • 首次给药24小时后采集脑脊液进行代谢组学分析。

研究设计与关键结果

  • 研究类型:对一项机构审查委员会批准的随机安慰剂对照试验(试验注册号NCT01322009)的脑脊液进行代谢组学分析。
  • 样本量:12例重型颅脑创伤患儿和5例年龄匹配对照。
  • 干预与对照:丙磺舒(25 mg/kg)联合N-乙酰半胱氨酸(140 mg/kg)经鼻/口胃管给药 vs 安慰剂。
  • 主要结果:与安慰剂组相比,丙磺舒联合N-乙酰半胱氨酸组脑脊液中有7条谷胱甘肽中心通路和2个网络富集;两成分主成分分析显示各组聚类,具有不同的代谢组学特征;鉴定出若干新的与颅脑创伤机制相关的通路;还鉴定出若干由丙磺舒可抑制转运体底物组成的额外通路/网络,提供机制验证。

证据类型、等级与局限

  • 证据类型:随机安慰剂对照试验的探索性代谢组学分析(概念验证性神经药理学代谢组学评估)。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,该概念验证性神经药理学代谢组学评估支持丙磺舒联合N-乙酰半胱氨酸治疗在儿童重型颅脑创伤中的治疗靶点 engagement。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To employ metabolomics-based pathway and network analyses to evaluate the cerebrospinal fluid metabolome after severe traumatic brain injury in children and the capacity of combination therapy with probenecid and N-acetylcysteine to impact glutathione-related and other pathways and networks, relative to placebo treatment.

DESIGN: Analysis of cerebrospinal fluid obtained from children enrolled in an Institutional Review Board-approved, randomized, placebo-controlled trial of a combination of probenecid and N-acetylcysteine after severe traumatic brain injury (Trial Registration NCT01322009).

SETTING: Thirty-six-bed PICU in a university-affiliated children's hospital.

PATIENTS AND SUBJECTS: Twelve children 2-18 years old after severe traumatic brain injury and five age-matched control subjects.

INTERVENTION: Probenecid (25 mg/kg) and N-acetylcysteine (140 mg/kg) or placebo administered via naso/orogastric tube.

MEASUREMENTS AND MAIN RESULTS: The cerebrospinal fluid metabolome was analyzed in samples from traumatic brain injury patients 24 hours after the first dose of drugs or placebo and control subjects. Feature detection, retention time, alignment, annotation, and principal component analysis and statistical analysis were conducted using XCMS-online. The software "mummichog" was used for pathway and network analyses. A two-component principal component analysis revealed clustering of each of the groups, with distinct metabolomics signatures. Several novel pathways with plausible mechanistic involvement in traumatic brain injury were identified. A combination of metabolomics and pathway/network analyses showed that seven glutathione-centered pathways and two networks were enriched in the cerebrospinal fluid of traumatic brain injury patients treated with probenecid and N-acetylcysteine versus placebo-treated patients. Several additional pathways/networks consisting of components that are known substrates of probenecid-inhibitable transporters were also identified, providing additional mechanistic validation.

CONCLUSIONS: This proof-of-concept neuropharmacometabolomics assessment reveals alterations in known and previously unidentified metabolic pathways and supports therapeutic target engagement of the combination of probenecid and N-acetylcysteine treatment after severe traumatic brain injury in children.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Hagos FT, Empey PE, Wang P, et al. Exploratory Application of Neuropharmacometabolomics in Severe Childhood Traumatic Brain Injury. Crit Care Med. 2018. PMID: 29742587. doi:10.1097/CCM.0000000000003203

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。